Category Research

Merck Unveils Clinical Trial Strategy for New HPV Vaccine and GARDASIL®9 Single-Dose Regimen

Merck (NYSE: MRK), also known as MSD outside the United States and Canada, made a significant announcement today at the EUROGIN 2024 HPV Congress. The company revealed its intentions to commence clinical development of a groundbreaking investigational multi-valent HPV vaccine…

Read MoreMerck Unveils Clinical Trial Strategy for New HPV Vaccine and GARDASIL®9 Single-Dose Regimen

The Chemical Quality Control Laboratory: Guardian of Standards in the Pharmaceutical Plant

The Role of Quality Control at Orion Pharmaceuticals Maija Blomquist, the Quality Control Manager for Materials, Gels & Ointments, underscores the pivotal role of quality control in maintaining Orion’s product standards. Acting as sentinels throughout the production cycle, her team…

Read MoreThe Chemical Quality Control Laboratory: Guardian of Standards in the Pharmaceutical Plant

Optimizing Project Management for Pharmaceutical Manufacturing: A Roadmap to Effective Clinical Trials

Unlocking Project Management’s Role in CDMOs In the intricate web of pharmaceutical and biotech industries, Contract Development and Manufacturing Organizations (CDMOs) stand as pivotal partners, offering indispensable services like API synthesis, formulation, and packaging—essentials for drug manufacturing. Project management emerges…

Read MoreOptimizing Project Management for Pharmaceutical Manufacturing: A Roadmap to Effective Clinical Trials

A First-of-Its-Kind Study Shows Skin Improvement in Over Two-Thirds of People with Atopic Dermatitis and Skin of Color Using Lebrikizumab

Eli Lilly and Company (NYSE: LLY) has disclosed findings from a pioneering investigation into lebrikizumab, tailored specifically for individuals with skin of color grappling with moderate-to-severe atopic dermatitis, commonly known as eczema. The study unveiled that lebrikizumab, an investigational treatment,…

Read MoreA First-of-Its-Kind Study Shows Skin Improvement in Over Two-Thirds of People with Atopic Dermatitis and Skin of Color Using Lebrikizumab

Oragenics, Inc. Readies Phase II Clinical Trials for Concussion Treatment Drug

Oragenics, Inc. (NYSE American: OGEN), a company dedicated to developing innovative intranasal pharmaceuticals for neurological disorders, has revealed its readiness to embark on the final stages of GMP manufacturing and formulation for its drug candidate, ahead of the anticipated Phase…

Read MoreOragenics, Inc. Readies Phase II Clinical Trials for Concussion Treatment Drug

AbbVie and OSE Immunotherapeutics Collaborate to Advance Novel Monoclonal Antibody for Chronic Inflammation Treatment

AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, have announced a strategic partnership aimed at developing OSE-230, a monoclonal antibody designed to address chronic and severe inflammation. Currently in the pre-clinical development…

Read MoreAbbVie and OSE Immunotherapeutics Collaborate to Advance Novel Monoclonal Antibody for Chronic Inflammation Treatment

FDA Prioritizes Review of Dupixent® sable for COPD Treatment Targeting Type 2 Inflammation

The U.S. Food and Drug Administration (FDA) has given priority review status to the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab), marking its sixth potential indication. This review targets its use as an add-on maintenance treatment for specific adult…

Read MoreFDA Prioritizes Review of Dupixent® sable for COPD Treatment Targeting Type 2 Inflammation

Revised WHO Recommendations for Managing Vector-Borne Diseases via Indoor Residual Spraying

Approximately 80% of the global population faces the threat of contracting one or more vector-borne diseases, with mosquitoes, flies, bugs, and other vectors transmitting viruses, parasites, and bacteria to millions worldwide. These diseases, including malaria, dengue, Chikungunya, yellow fever, Zika…

Read MoreRevised WHO Recommendations for Managing Vector-Borne Diseases via Indoor Residual Spraying